Refine
Year of publication
Document Type
- Article (117)
- Doctoral Thesis (7)
Language
- English (124) (remove)
Is part of the Bibliography
- no (124)
Keywords
- - (77)
- exercise (4)
- pancreatic ductal adenocarcinoma (4)
- FLT3-ITD (3)
- IPMN (3)
- Intraductal papillary mucinous neoplasm (3)
- PDAC (3)
- Sepsis (3)
- cardiopulmonary exercise testing (3)
- cardiorespiratory fitness (3)
- lipidomics (3)
- AML (2)
- BCL11B (2)
- Chemotherapy (2)
- Clinical guideline (2)
- Cystitis (2)
- DNA repair (2)
- Epidemiology (2)
- Fournier’s gangrene (2)
- Hyperbaric oxygenation (2)
- Inflammation (2)
- Necrotizing fasciitis (2)
- Necrotomy (2)
- Pancreas (2)
- Pancreatic cancer (2)
- Pyelonephritis (2)
- Soft tissue infection (2)
- Systematic review (2)
- Urinary tract infection (2)
- acute myeloid leukemia (2)
- acute pancreatitis (2)
- all-cause mortality (2)
- antares (2)
- bile acids (2)
- biomarker (2)
- cardiac output (2)
- cardiomyopathy (2)
- central blood pressure (2)
- chronic kidney disease (2)
- chronic pancreatitis (2)
- chronic thromboembolic pulmonary hypertension (2)
- comorbidities (2)
- epigenetics (2)
- erythrocytes (2)
- everolimus (2)
- fatty acids (2)
- fibrosis (2)
- heart failure (2)
- hemodialysis (2)
- immune response (2)
- inflammation (2)
- invasive (2)
- left ventricular hypertrophy (2)
- lung function (2)
- miRNA (2)
- nitric oxide (2)
- pancreatitis (2)
- prognosis (2)
- pulse wave analysis (2)
- resistance (2)
- sarcoma (2)
- therapy (2)
- transcription factor EB (2)
- validation (2)
- 17-AAG (1)
- 4 (1)
- 5-fluorouracil (1)
- <i>Janus kinase 2</i> (<i>JAK2</i>) (1)
- ADCC (1)
- ADPKD (1)
- AICC (1)
- ANC (1)
- Acute myeloid leukemia (AML) (1)
- Adenocarcinoma (1)
- Allogeneic stem cell transplantation (1)
- Alzheimer’s clinical syndrome (1)
- Apolipoprotein concentration (1)
- Autoantibodies (1)
- BDNF (1)
- BK virus (1)
- Biomarkers (1)
- Bone marrow metastasis (1)
- CFTR Cl (1)
- CKD (1)
- CLP (1)
- CPET (1)
- CRISPR-Cas9 (1)
- CRISPR/Cas (1)
- CVD biomarker (1)
- Cancerogenesis (1)
- Cardiorespiratory fitness (1)
- Cardiovascular disease (1)
- Cardiovascular rehabilitation (1)
- Case report (1)
- Cell culture (1)
- Cell death (1)
- Chromosomal aberrations (1)
- Chronic non-communicable diseases (1)
- Chronic obstructive pulmonary disease (1)
- Chronic pancreatitis (1)
- Citrus fruits (1)
- Cold-shock proteins (1)
- Combination chemotherapy (1)
- Cost-effectiveness (1)
- Critical illness myopathy (1)
- Cystic lesion (1)
- CytoSorb (1)
- Cytokines (1)
- DNA epair (1)
- DNA polymerase theta (1)
- DNA-Polymerase theta (1)
- DNA-Reparatur (1)
- DSB (1)
- Daratumumab (1)
- Deep Learning (1)
- Diagnosis (1)
- Disseminated intravascular coagulation (1)
- Docetaxel (1)
- Dyslipidemia (1)
- Dyspnea (1)
- ET (1)
- Early mobilization (1)
- Echocardiography (1)
- Eisenoxid-Nanopartikels (1)
- Electronic assessment (1)
- Energy mobilization (1)
- Environmental risk factors (1)
- Environmental toxins (1)
- Epithelioid sarcoma (1)
- Essential thrombocythemia (1)
- European soccer championship (1)
- Extracellular matrix (1)
- Extramedullary disease (1)
- FLT3 (1)
- FLT3-TKD (1)
- FMS-like tyrosine kinase 3 (1)
- FRET (1)
- Feasibility (1)
- Fick method (1)
- Fine tiling comparative genomic hybridization (1)
- Flavonols (1)
- GD2-CAR (1)
- GLIM (1)
- GMP (1)
- Galectin (1)
- Gastrointestinal oncology (1)
- Gastrointestinal stromal tumor (1)
- Gastrointestinal symptoms (1)
- Gastrointestinal tract (1)
- Gelatinase A (1)
- Gemcitabine (1)
- Gene mutation (1)
- HCM (1)
- HCO (1)
- HDAC = histone deacetylase (1)
- HDL (1)
- HSP90 (1)
- Haemorrhagic cystitis (1)
- Heart-liver axis (1)
- Hsp27 (1)
- ICER (1)
- ICUAW (1)
- ICU‐acquired weakness (1)
- IL-15 (1)
- IL-18 (1)
- Immune dysfunction (1)
- Immunoadsorption (1)
- Immunometabolism (1)
- Immunoproteasome (1)
- Incremental cost-effectiveness ratio (1)
- Inflammation-induced muscle atrophy (1)
- Inflammatory biomarkers (1)
- Inpatient cancer care (1)
- Interleukin-6 (1)
- Invasive cardiopulmonary exercise testing (1)
- Isoflavone (1)
- JAK2V617F (1)
- KMT2A-rearranged AML (1)
- KRAS (1)
- LAMS (1)
- LDL (1)
- Lactate (1)
- Left ventricular geometry and function (1)
- Left ventricular hypertrophy (1)
- Left ventricular mass (1)
- Ligation-mediated PCR (1)
- Lipid metabolism (1)
- Lipidomics (1)
- Lipolysis (1)
- Lipoprotein particles (1)
- Lipoprotein subclasses (1)
- Lymphoblastic leukaemia (1)
- MF (1)
- MMP2 (1)
- MPN (1)
- MRI-proton-density-fat-fraction (PDFF) (1)
- Malignant transformation (1)
- Medizin (1)
- Mensch (1)
- Metabolic myopathy (1)
- Metastasis (1)
- Mitochondriopathy (1)
- Mitochondrium (1)
- MuRF (1)
- Muscle atrophy (1)
- Muscle-Specific RING finger protein (1)
- Muskelkrankheit (1)
- Myelofibrosis (1)
- Myeloproliferative neoplasia (1)
- Myogenic differentiation (1)
- NADPH oxidases (NOX) (1)
- NF‐κB (1)
- NZO mice (1)
- Natural history (1)
- Neuromuscular electrical stimulation (1)
- Nox4 (1)
- Nuclear magnetic resonance spectroscopy (1)
- Nutritional risk factors (1)
- Oxidative stress (1)
- PAR1 (1)
- PI3K/AKT pathway (1)
- PKD (1)
- PLK1 (1)
- PRSS1 (1)
- PSMB8 (1)
- Palliative chemotherapy (1)
- Pancreatic cystic lesion (1)
- Pancreatic tumour (1)
- Pancreatitis (1)
- Pathophysiological relationship (1)
- Patient-reported outcomes (1)
- Phytochemicals (1)
- Phytotherapie (1)
- Plasmapheresis (1)
- Pomalidomide (1)
- Precision medicine (1)
- Prevention of cardiovascular diseases (1)
- Prevention of metabolic diseases (1)
- Prodigy (1)
- Prostatakarzinom (1)
- Proteasom (1)
- Protein Storage Disease (1)
- Protocol‐based physiotherapy (1)
- Pulmonary arterial hypertension (1)
- QUALI (1)
- Quality-adjusted life years (1)
- RRMM (1)
- Reactive oxygen species (ROS) (1)
- Recurrence (1)
- Residual risk (1)
- Risk factors (1)
- SH045 (1)
- SPINK1 (1)
- SPIONs (1)
- SPSB1 (1)
- STS (1)
- Sarcoma (1)
- Scribble (1)
- Small dense LDL (1)
- Soft tissue sarcoma (1)
- Soluble APRIL (1)
- Soluble BAFF (1)
- Sphingosine-1-phosphate (1)
- Surgery (1)
- Surgical trauma (1)
- Surgically induced immune dysfunction (1)
- Survival (1)
- TAC (1)
- TFE3 (1)
- TGFβ receptor II (1)
- TKI (1)
- TNF (1)
- TRPC6 (1)
- TRUCK (1)
- Targeted delivery (1)
- Theranostics (1)
- Therapy (1)
- Thrombocytopenia (1)
- Triple refractory (1)
- Trypsin (1)
- Tumor spezifischer Transport (1)
- Type-2 diabetes (1)
- UUO (1)
- Ubiquitin (1)
- VLDL (1)
- VPA (1)
- WON (1)
- Whole‐body vibration (1)
- YBX1 (1)
- adults (1)
- advanced gastroesophageal cancer (1)
- aging (1)
- alamandine (1)
- alpha- beta CD8+ T cells (1)
- angiogenesis (1)
- angiotensin II type 1a receptor (1)
- animal models (1)
- aquaporins (1)
- arterial smooth muscle (1)
- arterial stiffness (1)
- arterio-venous (1)
- atherosclerosis (1)
- atrial fibrillation (1)
- autoantibodies (1)
- autophagy-lysosomal pathway (1)
- autosomal-dominant polycystic kidney disease (1)
- bacterial infection (1)
- balloon pulmonary angioplasty (1)
- biased ligands (1)
- big data (1)
- bilirubin (1)
- bio-orthogonal click chemistry (1)
- bioassay-guided fractionation (1)
- biomaterial (1)
- biotransformation (1)
- bleeding (1)
- blood compatibility (1)
- blood pressure (1)
- blood purification (1)
- bone marrow microenvironment (1)
- bortezomib (1)
- calorimetry (1)
- cancer (1)
- cancer risk (1)
- cardiac index (1)
- cardiac remodelling (1)
- cardiomyogenic differentiation (1)
- cardiorespiratory exercise capacity (1)
- cardiovascular disease (1)
- casein kinase II (1)
- caveolae (1)
- central hemodynamics (1)
- chemotherapy (1)
- chiral metabolism (1)
- chromatin (1)
- chromoplexy (1)
- chromosomal translocations (1)
- chromosome conformation capture (1)
- chronic inflammation (1)
- chronic kidney disease (CKD) (1)
- chronic periodontitis (1)
- chronic thromboembolic pulmonary disease (1)
- citrulline (1)
- clinically important restrictions and symptoms (1)
- coagulation (1)
- complement activation (1)
- complex lipids (1)
- congenital heart disease (1)
- crenolanib (1)
- cross-sectional study (1)
- cutaneous T-cell lymphoma (1)
- cyclin dependent kinase (1)
- cytokine adsorption (1)
- deep sequencing (1)
- dementia (1)
- dialysis (1)
- differentiation (1)
- dilated cardiomyopathy (1)
- diurnal rhythm (1)
- droplet microfluidics (1)
- duktale Adenokarzinom des Pankreas (1)
- dyspnea (1)
- eating behaviour (1)
- echocardiography (1)
- eicosanoids (1)
- emotional stress (1)
- endoscopic characteristics (1)
- endothelial activation (1)
- endothelium (1)
- enteral nutrition (1)
- erythrocyte (1)
- essential thrombocythemia (ET) (1)
- estradiol; (1)
- experimental pancreatitis (1)
- extracorporeal life support (1)
- fat-free mass (1)
- fetal zone steroids; (1)
- flow‐mediated dilation (1)
- gastrointestinal lymphoma (1)
- gemcitabine (1)
- gene expression (1)
- general population (1)
- genetic predisposition (1)
- gilteritinib (1)
- gut microbiota (1)
- handgrip strength (1)
- health-related quality of life (1)
- heart failure with preserved ejection fraction (1)
- heart rate (1)
- hematologic malignancies (1)
- hematopoiesis (1)
- hemoadsorption (1)
- hereditary pancreatitis (1)
- high‐risk (1)
- histone variants (1)
- histopathology (1)
- holobiont (1)
- homoarginine (1)
- homodimerization (1)
- human (1)
- hyaluronic acid microgels (1)
- hyperoxia (1)
- hypertension (1)
- idiopathic pulmonary fibrosis (1)
- immune system (1)
- immunoadsorption (1)
- immunoproteasome (iP) (1)
- in vitro testing (1)
- inflammatory bowel diseases (1)
- innateness (1)
- interstitial lung disease (1)
- interventional EUS (1)
- invasive cardiopulmonary exercise testing (1)
- ketamine (1)
- kinase inhibitors (1)
- knock-out (1)
- leukocyte activation (1)
- liver failure (1)
- liver fat content (1)
- liver support (1)
- longitudinal cohort study (1)
- machine learning (1)
- macroH2A (1)
- macrodomain (1)
- malignant transformation (1)
- malnutrition (1)
- mechanical circulatory support (1)
- mesenteric artery (1)
- metabolic subtypes (1)
- metabolomics (1)
- metastatic colorectal cancer (1)
- microRNA sequencing (1)
- microarray (1)
- microbiome (1)
- microbiota (1)
- microdialysis (1)
- midostaurin (1)
- molecular biology (1)
- monocytes (1)
- multiple myeloma (1)
- muscle atrophy (1)
- muscle ring finger protein 1 (1)
- myeloid differentiation factor 2 (1)
- myeloproliferative neoplasms (MPN) (1)
- myogenic vasoconstriction (1)
- neuropathy (1)
- non-homologous end joining (1)
- non-interventional (1)
- observational (1)
- observational study (1)
- oligodendrocyte precursor cells (1)
- oligomeric proanthocyanidines (1)
- oncohistone (1)
- oxidative stress (1)
- oxygen uptake (1)
- oxylipins (1)
- paclitaxel (1)
- pancreas (1)
- parenteral nutrition (1)
- peak oxygen uptake (1)
- pediatric intestinal failure (1)
- pediatric short bowel syndrome (1)
- percutaneous coronary intervention (1)
- perivascular adipose tissue (1)
- personalised medicine (1)
- pharmacokinetic modeling (1)
- phenotyping (1)
- platelet activation (1)
- platelet–monocyte aggregates (1)
- polarity regulators (1)
- poly-(L-lactide); (1)
- polycythemia vera (PV) (1)
- population-based (1)
- population-based imaging (1)
- prediction (1)
- predictive marker (1)
- preterm birth (1)
- primary myelofibrosis (PMF) (1)
- prognostic factors (1)
- prognostic marker (1)
- prolonged release (1)
- prospective (1)
- protease-activated receptors (1)
- proteasome inhibitors (PIs) (1)
- protein aggregate myopathy (1)
- protein degradation (1)
- protein expression and purification (1)
- protein kinase D (1)
- proteomics (1)
- proton pump inhibitor (1)
- pulmonary arterial hypertension (1)
- pulmonary arterial pressure (1)
- pulmonary endarterectomy (1)
- pulmonary hypertension (1)
- pulmonary vascular resistance (1)
- pyrimidine (1)
- quizartinib (1)
- radiomics (1)
- rapamycin (1)
- rare disease (1)
- regenerative medicine (1)
- renal denervation (1)
- renal dysfunction (1)
- renin-angiotensin system (1)
- responders/non-responders (1)
- right heart catheter (1)
- riociguat (1)
- risk factor progression (1)
- sarcopenia (1)
- second‐line (1)
- sedentarism (1)
- sex-based difference (1)
- shear stress (1)
- soluble guanylyl cyclase (1)
- soluble guanylyl cyclase activator (1)
- soluble guanylyl cyclase stimulator (1)
- speckle-tracking (1)
- sphingolipids (1)
- spp. (1)
- stem cells (1)
- stent (1)
- stiffness (1)
- survival (1)
- targeted therapy (1)
- telemetry (1)
- thermodilution (1)
- thrombin (1)
- thrombo-inflammation (1)
- thromboembolism (1)
- thrombosis (1)
- titin (1)
- toll-like receptor 4 (1)
- toll-like receptors (1)
- tooth loss (1)
- trabectedin (1)
- trifunctionality (1)
- tumor suppressor (1)
- tunicamycin (1)
- ubiquitin-proteasome system (1)
- ubiquitin–proteasome system (UPS) (1)
- vascular inflammation (1)
- ventilation (1)
- vorapaxar (1)
- weight loss (1)
- whole-body magnetic resonance imaging (1)
- wild‐type (1)
- zinc finger (1)
- Überlebenszeit , Prognose , Ultraschallkardiografie (1)
- α1-Adrenergic receptor (1)
Institute
- Kliniken und Polikliniken für Innere Medizin (124) (remove)
Publisher
- MDPI (41)
- S. Karger AG (20)
- Wiley (15)
- Frontiers Media S.A. (12)
- Nature Publishing Group (9)
- Springer Nature (5)
- BioMed Central (BMC) (3)
- SAGE Publications (3)
- BMJ Publishing Group (1)
- Elsevier (1)
Chromosomal abnormalities, like deletions, amplifications, inversions or translocations, are recurrent features in haematological malignancies. However, the precise molecular breakpoints are frequently not determined. Here we describe a rapid analysis of genetic imbalances combining fine tiling comparative genomic hybridization (FT-CGH) and ligation-mediated PCR (LM-PCR). We clarified an inv(14)(q11q32) in a case of T cell acute lymphoblastic leukaemia with a breakpoint in the TRA/D in 68% of cells detected by fluorescence in situ hybridization. FT-CGH showed several mono- and biallelic losses within TRA/D. LM-PCR disclosed a TRA/D rearrangement on one allele. The other allele revealed an inv(14)(q11q32), joining TRDD2 at 21,977,000 of 14q11 together with the IGH locus at 105,948,000 and 3′-sequence of TRAC at 22,092,000 joined together with IGHV4–61 at 106,166,000. This sensitive approach can unravel complex chromosomal abnormalities in patient samples with a limited amount of aberrant cells and may lead to better diagnostic and therapeutic options.
Chronic pancreatitis has long been thought to be mainly associated with immoderate alcohol consumption. The observation that only ∼10% of heavy drinkers develop chronic pancreatitis not only suggests that other environmental factors, such as tobacco smoke, are potent additional risk factors, but also that the genetic component of pancreatitis is more common than previously presumed. Either disease-causing or protective traits have been indentified for mutations in different trypsinogen genes, the gene for the trypsin inhibitor SPINK1, chymotrypsinogen C, and the cystic fibrosis transmembane conductance regulator (CFTR). Other factors that have been proposed to contribute to pancreatitis are obesity, diets high in animal protein and fat, as well as antioxidant deficiencies. For the development of pancreatic cancer, preexisting chronic pancreatitis, more prominently hereditary pancreatitis, is a risk factor. The data on environmental risk factors for pancreatic cancer are, with the notable exception of tobacco smoke, either sparse, unconfirmed or controversial. Obesity appears to increase the risk of pancreatic cancer in the West but not in Japan. Diets high in processed or red meat, diets low in fruits and vegetables, phytochemicals such as lycopene and flavonols, have been proposed and refuted as risk or protective factors in different trials. The best established and single most important risk factor for cancer as well as pancreatitis and the one to clearly avoid is tobacco smoke.
Background: Patients with mucin-producing adenocarcinoma have an increased risk for venous and arterial thrombosis. When these patients present with thrombocytopenia, disseminated intravascular coagulopathy (DIC) is often the underlying cause. Case Report: We report 2 patients who were admitted due to bleeding symptoms of unknown cause, in whom further workup revealed adenocarcinoma-induced DIC. Conclusion: In elderly patients presenting with signs of DIC, such as reduced fibrinogen levels, elevated prothrombin time, elevated D-dimer, and thrombocytopenia, without any obvious reason (e.g., sepsis), adenocarcinoma-associated coagulopathy should be considered as the underlying cause. Paradoxically, in these patients bleeding symptoms improve when the patient is sufficiently anti-coagulated with low molecular weight heparin. Treatment of the underlying disease is of central importance in controlling acute or chronic DIC associated with malignant diseases and chemotherapy should be started as soon as possible.
Objective: Epithelioid sarcoma (ES) presents unique clinical features in comparison to other sarcoma subtypes. Data regarding the benefits of chemotherapy are very limited. Combination regimens using gemcitabine and docetaxel (Gem/Doce) have proven to be effective, especially in uterine and nonuterine leiomyosarcoma. Yet, there is no available data on the efficacy of Gem/Doce in ES. Methods: A retrospective analysis of the three participating institutions was performed. Twenty-eight patients with an ES diagnosis presented at one of the participating institutions between 1989 and 2012. Of this group, 17 patients received chemotherapy. Results: Patients' median overall survival (OS) after the beginning of palliative chemotherapy was 21 months, and the 1-year OS was 87%. Twelve patients received Gem/Doce with a clinical benefit rate of 83%. The median progression-free survival (PFS) was 8 months for all patients receiving Gem/Doce. The best response was complete remission in 1 patient and partial remission in 6 patients. All 6 patients receiving Gem/Doce as a first-line treatment showed measurable responses with a median PFS of 9 months. Conclusions: In this retrospective study, Gem/Doce was an effective chemotherapeutic regimen for ES. Prospective studies are needed to better assess the effects of this combination drug therapy.
Inflammation is part of the body's immune response in order to remove harmful stimuli—like pathogens, irritants or damaged cells—and start the healing process. Recurrent or chronic inflammation on the other side seems a predisposing factor for carcinogenesis and has been found associated with cancer development. In chronic pancreatitis mutations of the cationic trypsinogen (PRSS1) gene have been identified as risk factors of the disease. Hereditary pancreatitis (HP) is a rare cause of chronic pancreatic inflammation with an early onset, mostly during childhood. HP often starts with recurrent episodes of acute pancreatitis and the clinical phenotype is not very much different from other etiologies of the disease. The long-lasting inflammation however generates a tumor promoting environment and represents a major risk factor for tumor development This review will reflect our knowledge concerning the specific risk of HP patients to develop pancreatic cancer.
Background: Abdominal surgery is frequently followed by immune dysfunction usually lasting for several days. This is especially important in cases with tumour diseases as an intact immune function is essential in this situation. Therefore, we analysed the outcome of tumour-bearing mice in a mouse model of surgically induced immune dysfunction (SID). Methods: In male C57BL/6 mice, a pancreatic tumour was implanted orthotopically. Following tumour implantation, the model of SID was applied. The control groups were either laparotomised or underwent no surgical procedure. The survival rate was determined by observation for >60 days. The tumour growth progress was imaged by a 7-tesla small animal MRI. Results: On day 60 after tumour implantation, the survival rate in SID mice was reduced to 41%. In the laparotomised group, 81% of mice survived, while the control group had a survival rate of 75%. These differences were significant (SID vs. control: p < 0.02, and SID vs. laparotomy: p < 0.002). The tumour volume was not influenced by the degree of surgical trauma. Conclusion: In pancreatic cancer, the SID model is ideally suited to investigate the influence of SID on this tumour entity.
Chronic Obstructive Pulmonary Disease and Diabetes Mellitus: A Systematic Review of the Literature
(2015)
The objective of this systematic review was to discuss our current understanding of the complex relationship between chronic obstructive pulmonary disease (COPD) and type-2 diabetes mellitus (T2DM). We performed a systematic search of the literature related to both COPD and diabetes using PubMed. Relevant data connecting both diseases were compiled and discussed. Recent evidence suggests that diabetes can worsen the progression and prognosis of COPD; this may result from the direct effects of hyperglycemia on lung physiology, inflammation or susceptibility to bacterial infection. Conversely, it has also been suggested that COPD increases the risk of developing T2DM as a consequence of inflammatory processes and/or therapeutic side effects related to the use of high-dose corticosteroids. In conclusion, although there is evidence to support a connection between COPD and diabetes, additional research is needed to better understand these relationships and their possible implications.
Background: With the use of modern cross-sectional abdominal imaging modalities, an increasing number of cystic pancreatic lesions are identified incidentally. Although there is no pathological diagnosis available in most cases, it is believed that the majority of these lesions display small branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) of the pancreas. Even though a number of large clinical series have been published, many uncertainties remain with regard to this entity of mucinous cystic neoplasms. Methods: Systematic literature review. Results: Main-duct (MD) and mixed-type IPMNs harbor a high risk of malignant transformation. It is conceivable that most IPMNs with involvement of the main duct tend to progress to invasive carcinoma over time. Thus, formal oncologic resection is the treatment of choice in surgically fit patients. In contrast, the data regarding BD-IPMN remain equivocal, resulting in conflicting concepts. To date, it is not clear whether and which BD-IPMNs progress to carcinoma and how long this progression takes. Conclusion: While patients with MD-IPMNs should undergo surgical resection if comorbidities and life expectancy permit this, the management of small BD-IPMNs remains controversial. Population-based studies with long-term follow-up are needed to define which cohort of patients can be observed safely without immediate resection.
The Clinical and Socio-Economic Relevance of Increased IPMN Detection Rates and Management Choices
(2015)
Background: Increased usage of computed tomography and magnetic resonance imaging has led to a large increase in identified pancreatic cysts of up to 25% in population-based studies. The clinical and economic relevance of identifying so many cystic lesions has not been established. Compared to other organs such as liver or kidney, dysontogenetic pancreatic cysts are rare. Pancreatic cysts comprise a variety of benign, premalignant or malignant lesions; however, precise diagnosis before resection has an accuracy of only 80%. The focus of recent research was the malignant potential of intraductal papillary mucinous neoplasms (IPMN) with the aim of establishing clinical pathways addressing risk of malignancy, age and comorbidity, treatment-related morbidity and mortality as well as cost-effectiveness of treatment and surveillance. The focus of this review is to analyze the clinical and socio-economic relevance as well as the cost-benefit relation for IPMNs. Methods: For analysis, the following MESH terms were used to identify original articles, reviews, and guidelines in PubMed: (‘intraductal papillary mucinous neoplasm' OR ‘pancreatic cysts') and (incidence OR relevance OR socio-economic OR economic OR cost-effectiveness OR cost-benefit). The retrieved publications were reviewed with a focus on clinical and socio-economic relevance in relation to the increasing incidence of IPMN. Results: Addressing the increasing prevalence of pancreatic cystic lesions, recent consensus guidelines suggested criteria for risk stratification according to ‘worrisome features' and ‘high-risk stigmata'. Recent prospective cohort studies evaluated whether these can be applied in clinical practice. Evaluation of three different clinical scenarios with regard to costs and quality-adjusted life years suggested a better effectiveness of surveillance after initial risk stratification by endoscopic ultrasound-guided fine-needle aspiration with cyst fluid analysis compared with immediate resection or follow-up without further intervention. Of interest, the ‘immediate surgery' strategy was lowest for cost-effectiveness. Conclusions: The increasing incidence of identified pancreatic cysts requires an improved strategy for non-invasive risk stratification based on advanced imaging strategies. In light of a malignancy risk of 2% for branch-duct IPMN, the socio-economic necessity of a balance between surveillance and resection has to be agreed on.